Competition
Competition — Mirae Corporation (025560)
Competitive Bottom Line
Mirae has no durable moat. It is the smallest listed name among the five test-handler vendors active in Korea (Mirae, JT, Techwing, AMT, Advantest — all named in Mirae's own FY2025 DART business report), and across the broader back-end test ecosystem it sits two to three orders of magnitude below the relevant scale benchmarks. The single competitive fact that explains FY2025's 18% operating margin, four-fold ATE shipment jump, and ₩50.8B revenue print is that one Chinese customer (YILINING PRECISION, 56.5% of revenue) chose Mirae over a Chinese domestic handler maker like Changchuan. The competitor that matters most to the next 24 months is therefore not Advantest, Cohu, or even Techwing — it is Changchuan Technology (Shanghai-listed) and the wider Chinese domestic handler industry, subsidised, sanctions-protected, and gaining on the same wave that floated Mirae in FY2025.
The Right Peer Set
The five comparators below were chosen because they share customers (memory IDMs + OSATs), share the back-end cycle, or are explicitly named as Mirae's competitors in its own FY2025 DART business report. The Korean back-end ecosystem peers (Hanmi, ISC) compete for the same customer capex wallet but with different products — they are not "handler competitors" but are the reference points investors use to judge whether a Korean back-end equipment vendor is winning.
Two named competitors are missing from the public peer set: JT Corporation (KOSDAQ 089790) is a direct test-handler peer named alongside Techwing in Mirae's AR; we held it as a documented alternative rather than swap it for any of the five comparators that have stronger Korean-back-end signal value. AMT is private/unlisted and has no comparable financials. Changchuan Technology (300604.SZ) is the Chinese champion that matters most for Mirae's China revenue but did not pass through the staged-data pipeline; it is flagged in the Threat Map and in the unresolved-question queue.
Market caps and EV from data/competition/peer_valuations.json (USD values converted at 2026-05-13 FX). Mirae market cap = 4.47M shares × ₩27,600 = ₩123.4B (~US$82.8M). Hanmi, ISC, Techwing, Mirae values in millions of KRW; Advantest in millions of JPY; Cohu in millions of USD. Source filings: Mirae FY2025 DART 사업보고서, Cohu FY2025 10-K, Advantest IAR2025, Hanmi/Techwing/ISC FY2025 DART 사업보고서.
The map shows Mirae bottom-left: the smallest revenue, a respectable cycle-peak margin, and the smallest market cap by an order of magnitude. The two profit-pool winners (Hanmi, Advantest) are top-right. Cohu is the cautionary case — biggest pure-play handler revenue but loss-making at the bottom of the cycle, proving that handler scale alone does not bring durable profits.
Where The Company Wins
Mirae's wins are narrow, real, and almost entirely commercial, not technological. There is no proprietary node, no patent moat, no captive customer base. What Mirae has are four operational advantages that matter in specific deals.
Read this list carefully. Three of four "advantages" are price-driven or regulation-driven — none are technological. The closest thing to a moat is the Korea-vs-US-vs-China supplier-origin advantage in YILINING-type accounts, and that disappears the moment Korean-sourced back-end test equipment lands on a future BIS controlled-end-use list, or YILINING reaches scale where it switches to Changchuan for cost.
Where Competitors Are Better
Every comparator in the peer set has at least one structural attribute that Mirae cannot match without years of investment.
Cohu R&D ₩137B figure converts US$92.2M at ~1,490 KRW/USD. Advantest R&D is estimated from segmental reporting and IAR2025 disclosure (FY2026 figure converted from JPY). Mirae and Korean peer R&D figures from each company's FY2025 DART 사업보고서 연구개발활동 section.
The intensity chart explains why Mirae's product roadmap is shallow: Hanmi spends 8× Mirae's R&D in absolute KRW, and they spend it on the part of the market (HBM) that is winning. Cohu and Techwing each have R&D budgets 5-7× Mirae's despite being smaller-cap than Hanmi or Advantest, which means even the down-cycle players continue to invest at multiples of what Mirae can fund.
Threat Map
The threats below are ranked by severity over the next 24 months. The top two are the only ones that can move Mirae's equity value materially.
The threat that matters most is the one with no direct peer in this table. Changchuan Technology is the Chinese domestic handler champion that competes for the same YILINING-class customers as Mirae and is being actively subsidised through Big Fund Phase III. Mirae's competitive position in China is structurally borrowed time. The peer set above gives investors a fair read on Mirae versus listed comparables, but the company that decides whether Mirae's FY2025 outperformance repeats is Shanghai-listed and not in this peer table.
Moat Watchpoints
Five measurable signals tell the investor whether Mirae's already-thin competitive position is improving or deteriorating. None of them require management commentary — every one is observable in DART filings, industry data, or competitor disclosures.
The simplest test of the Mirae competitive thesis. If, by FY2026 year-end, (a) YILINING PRECISION concentration is below 50%, (b) at least one HBM-specific handler product has been announced, and (c) absolute R&D has grown to ₩5B or more — the moat is widening from thin to defensible. If those three readings are unchanged or worse, Mirae remains what it is today: a Korean job-shop handler vendor with one Chinese customer, no HBM story, and an R&D budget five-to-seven times below the smallest peer that has either.